Original language | English |
---|---|
Journal | Journal of the Canadian Urological Association |
Volume | 14 |
Issue number | 2 |
DOIs | |
Publication status | Published - 2020 |
Externally published | Yes |
ASJC Scopus Subject Areas
- Urology
Access to Document
Other files and links
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
In: Journal of the Canadian Urological Association, Vol. 14, No. 2, 2020.
Research output: Contribution to journal › Review article › peer-review
}
TY - JOUR
T1 - Canadian Urological Association-Canadian Urologic Oncology Group guideline on Metastatic castration-naive and castration-sensitive prostate cancer
AU - So, Alan
AU - Chi, Kim
AU - Danielson, Brita
AU - Fleshner, Neil
AU - Kapoor, Anil
AU - Niazi, Tamim
AU - Pouliot, Frederic
AU - Rendon, Ricardo
AU - Shayegan, Bobby
AU - Sridhar, Srikala
AU - Vigneault, Eric
AU - Saad, Fred
N1 - Funding Information: Dr. So has been an advisory board member for Abbvie, Amgen, Astellas, Bayer, Janssen, Ferring, and TerSera; and has participated in clinical trials supported by Astellas, Ferring, and Janssen. Dr. Chi has received honoraria from Astellas, Bayer, Janssen, and Sanofi; and has participated in clinical trials supported by Astellas, AstraZeneca, Bayer, Eli Lilly, Essa, Janssen, Merck, Novartis, Pfizer, Roche, and Sanofi.Dr. Danielson has received advisory board honoraria and speaker fees from Amgen, Astellas, Bayer, and Janssen. Dr. Fleshner has been a consultant or advisory board member for Abbvie, Amgen, Astellas, Bayer, Ferring, Hybridyne Health, Janssen, and Sanofi; and has participated in clinical trials supported by Astellas, Bavarian Nordic, Bayer, Ferring, Janssen, Medivalion, Nucleix, Progenics Pharmaceutical, Sanofi, and Spectracure AB. Dr. Kapoor has been an advisory board member for BMS, Eisai, Ipsen, Merck, Novartis, Pfizer, and Roche; a speakers’ bureau member for Eisai, Ipsen, Novartis, and Roche; and has received grants/honoraria from BMS, Eisai, Ipsen, Merck, Novartis, Pfizer, and Roche. Dr. Niazi has received research grants and honoraria from Abbvie, Amgen, Astellas, Astra Zeneca, Bayer, Janssen, and Sanofi; and has participated in clinical trials supported by Astellas, Ferring, Janssen, and Sanofi. Dr. Pouliot has been an advisory board member for Amgen, Astellas, Bayer, and Janssen; has received payment from Abbott, Amgen, Astellas, Astra Zeneca, Bayer, Ferring, Janssen, and Sanofi; has received grants from Astra Zeneca and Sanofi; and has participated in clinical trials supported by Astellas, Bayer, Ferring, and Janssen. Dr. Rendon has been an advisory board and speakers’ bureau member for and has received honoraria from Abbvie, Amgen, Astellas, Astra Zeneca, Bayer, Ferring, Jansen, and Sanofi. Dr. Shayegan has been an advisory board member for Astellas, Bayer, and Janssen; and has received a research grant from Janssen. Dr. Shayegan has been an advisory board member for Astellas, Bayer, and Janssen; and has received a research grant from Janssen. Dr. Sridhar has been an advisory board member for Astellas, AstraZeneca, Bayer, Janssen, Merck, and Roche; and has participated in several pharma-supported clinical trials. Dr. Vigneault has been an advisory board member for Abbvie, Bayer, Ferring, and Sanofi. Dr. Saad has been an advisory board member for and has received payment/honoraria from Abbvie, Amgen, Astellas, Bayer, Janssen, and Sanofi; and has participated in clinical trials supported by Amgen, Astellas, Bayer, Janssen, and Sanofi.
PY - 2020
Y1 - 2020
UR - http://www.scopus.com/inward/record.url?scp=85077437297&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85077437297&partnerID=8YFLogxK
U2 - 10.5489/CUAJ.6384
DO - 10.5489/CUAJ.6384
M3 - Review article
AN - SCOPUS:85077437297
SN - 1911-6470
VL - 14
JO - Journal of the Canadian Urological Association
JF - Journal of the Canadian Urological Association
IS - 2
ER -